Found: 32
Select item for more details and to access through your institution.
Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine.
- Published in:
- Toxins, 2024, v. 16, n. 5, p. 221, doi. 10.3390/toxins16050221
- By:
- Publication type:
- Article
Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization.
- Published in:
- Journal of Headache & Pain, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s10194-024-01772-9
- By:
- Publication type:
- Article
Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population.
- Published in:
- Journal of Headache & Pain, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s10194-024-01727-0
- By:
- Publication type:
- Article
Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
- Published in:
- Cephalalgia, 2024, v. 44, n. 2, p. 1, doi. 10.1177/03331024231222923
- By:
- Publication type:
- Article
Migraine worsening after COVID‐19 and COVID‐19 vaccination: Are we facing a nocebo effect?
- Published in:
- European Journal of Neurology, 2023, v. 30, n. 12, p. 3877, doi. 10.1111/ene.16058
- By:
- Publication type:
- Article
Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01618-w
- By:
- Publication type:
- Article
Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
- Published in:
- Cephalalgia, 2023, v. 43, n. 8, p. 1, doi. 10.1177/03331024231177636
- By:
- Publication type:
- Article
Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome.
- Published in:
- European Journal of Neurology, 2023, v. 30, n. 7, p. 1937, doi. 10.1111/ene.15816
- By:
- Publication type:
- Article
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01585-2
- By:
- Publication type:
- Article
Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache.
- Published in:
- Cephalalgia, 2023, v. 43, n. 3, p. 1, doi. 10.1177/03331024221150235
- By:
- Publication type:
- Article
Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.
- Published in:
- Annals of Neurology, 2022, v. 92, n. 5, p. 846, doi. 10.1002/ana.26472
- By:
- Publication type:
- Article
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 10, p. 1395, doi. 10.1111/head.14404
- By:
- Publication type:
- Article
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
- Published in:
- Cephalalgia, 2022, v. 42, n. 3, p. 186, doi. 10.1177/03331024211040467
- By:
- Publication type:
- Article
Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability.
- Published in:
- Journal of Neurology, 2022, v. 269, n. 3, p. 1456, doi. 10.1007/s00415-021-10715-2
- By:
- Publication type:
- Article
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01366-9
- By:
- Publication type:
- Article
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01328-1
- By:
- Publication type:
- Article
The impact of a digital platform on migraine patient‐centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1403, doi. 10.1111/head.14225
- By:
- Publication type:
- Article
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
- Published in:
- Journal of Neurology, 2021, v. 268, n. 10, p. 3789, doi. 10.1007/s00415-021-10523-8
- By:
- Publication type:
- Article
Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 8, p. 1277, doi. 10.1111/head.14197
- By:
- Publication type:
- Article
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01267-x
- By:
- Publication type:
- Article
Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01289-5
- By:
- Publication type:
- Article
Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study.
- Published in:
- European Journal of Neurology, 2021, v. 28, n. 7, p. 2378, doi. 10.1111/ene.14828
- By:
- Publication type:
- Article
Neurophysiological correlates of abnormal auditory processing in episodic migraine during the interictal period.
- Published in:
- Cephalalgia, 2021, v. 41, n. 1, p. 45, doi. 10.1177/0333102420951509
- By:
- Publication type:
- Article
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Wear‐Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 8, p. 1673, doi. 10.1111/head.13925
- By:
- Publication type:
- Article
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01157-8
- By:
- Publication type:
- Article
How Does Migraine Change After 10 Years? A Clinical Cohort Follow‐Up Analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 5, p. 916, doi. 10.1111/head.13774
- By:
- Publication type:
- Article
When does chronic migraine strike?
- Published in:
- 2020
- By:
- Publication type:
- letter
Short and Mid‐Term Predictors of Response to OnabotulinumtoxinA: Real‐Life Experience Observational Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 4, p. 677, doi. 10.1111/head.13765
- By:
- Publication type:
- Article
Self-reported periodontitis and migraine: results from a multicenter, cross-sectional survey in Spain.
- Published in:
- Odontology, 2019, v. 107, n. 4, p. 530, doi. 10.1007/s10266-019-00430-w
- By:
- Publication type:
- Article
Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study).
- Published in:
- 2019
- By:
- Publication type:
- journal article
OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse.
- Published in:
- Frontiers in Neurology, 2018, p. N.PAG, doi. 10.3389/fneur.2018.00808
- By:
- Publication type:
- Article